Expression of CD40, CD138/syn-1, BCL-6, and LMP1 by RS Cells of HIV-HD
| Case No. . | HD Subtype . | Phenotype . | CD40 (%)* . | syn-1 (%)* . | BCL-6 (%)* . | LMP1 (%)* . | EBV† . |
|---|---|---|---|---|---|---|---|
| 1 | MC | B | >75 | >75 | 0 | 25-50 | + |
| 2 | MC‡ | B | >75 | >75 | 0 | >75 | + |
| 3 | MC‡ | B | >75 | 25-50 | 0 | 50-75 | + |
| 4 | MC | UD | >75 | 25-50 | 0 | 25-50 | + |
| 5 | MC | UD | >75 | 10-25 | 0 | 0 | − |
| 6 | MC1-153 | UD | >75 | 50-75 | <10 | >75 | + |
| 7 | MC | UD | >75 | <10 | 0 | <10 | + |
| 8 | MC‡ | UD | >75 | 50-75 | 0 | 50-75 | + |
| 9 | MC | UD | 50-75 | <10 | 0 | <10 | + |
| 10 | MC | UD | >75 | >75 | 0 | 50-75 | + |
| 11 | MC | UD | >75 | 25-50 | 0 | 25-50 | + |
| 12 | MC | UD | 50-75 | 50-75 | 0 | <10 | + |
| 13 | MC‡ | UD | 50-75 | 10-25 | 0 | 10-25 | + |
| 14 | MC | UD | >75 | 50-75 | <10 | 10-25 | + |
| 15 | MC1-153 | UD | >75 | 10-25 | 0 | 50-75 | + |
| 16 | MC | UD | 50-75 | >75 | 0 | <10 | + |
| 17 | LD | B | >75 | <10 | 0 | 50-75 | + |
| 18 | LD | B | >75 | 25-50 | 0 | >75 | + |
| 19 | LD | B | >75 | 50-75 | 0 | >75 | + |
| 20 | LD | B | >75 | >75 | 0 | 0 | − |
| 21 | LD | UD | 50-75 | <10 | 0 | >75 | + |
| 22 | LD | UD | 50-75 | <10 | 0 | >75 | + |
| 23 | LD | UD | 50-75 | <10 | 0 | <10 | + |
| 24 | LD | UD | 50-75 | 25-50 | 0 | >75 | + |
| 25 | LD | UD | >75 | >75 | 0 | >75 | + |
| 26 | NS | UD | >75 | >75 | 0 | <101-155 | + |
| 27 | NS | UD | >75 | <10 | 0 | <10 | + |
| Case No. . | HD Subtype . | Phenotype . | CD40 (%)* . | syn-1 (%)* . | BCL-6 (%)* . | LMP1 (%)* . | EBV† . |
|---|---|---|---|---|---|---|---|
| 1 | MC | B | >75 | >75 | 0 | 25-50 | + |
| 2 | MC‡ | B | >75 | >75 | 0 | >75 | + |
| 3 | MC‡ | B | >75 | 25-50 | 0 | 50-75 | + |
| 4 | MC | UD | >75 | 25-50 | 0 | 25-50 | + |
| 5 | MC | UD | >75 | 10-25 | 0 | 0 | − |
| 6 | MC1-153 | UD | >75 | 50-75 | <10 | >75 | + |
| 7 | MC | UD | >75 | <10 | 0 | <10 | + |
| 8 | MC‡ | UD | >75 | 50-75 | 0 | 50-75 | + |
| 9 | MC | UD | 50-75 | <10 | 0 | <10 | + |
| 10 | MC | UD | >75 | >75 | 0 | 50-75 | + |
| 11 | MC | UD | >75 | 25-50 | 0 | 25-50 | + |
| 12 | MC | UD | 50-75 | 50-75 | 0 | <10 | + |
| 13 | MC‡ | UD | 50-75 | 10-25 | 0 | 10-25 | + |
| 14 | MC | UD | >75 | 50-75 | <10 | 10-25 | + |
| 15 | MC1-153 | UD | >75 | 10-25 | 0 | 50-75 | + |
| 16 | MC | UD | 50-75 | >75 | 0 | <10 | + |
| 17 | LD | B | >75 | <10 | 0 | 50-75 | + |
| 18 | LD | B | >75 | 25-50 | 0 | >75 | + |
| 19 | LD | B | >75 | 50-75 | 0 | >75 | + |
| 20 | LD | B | >75 | >75 | 0 | 0 | − |
| 21 | LD | UD | 50-75 | <10 | 0 | >75 | + |
| 22 | LD | UD | 50-75 | <10 | 0 | >75 | + |
| 23 | LD | UD | 50-75 | <10 | 0 | <10 | + |
| 24 | LD | UD | 50-75 | 25-50 | 0 | >75 | + |
| 25 | LD | UD | >75 | >75 | 0 | >75 | + |
| 26 | NS | UD | >75 | >75 | 0 | <101-155 | + |
| 27 | NS | UD | >75 | <10 | 0 | <10 | + |
Abbreviations: UD, undetermined (non–B/non–T-cell phenotype); B, B-cell phenotype.
The percentage of CD40+, syn-1+, BCL-6+, and LMP1+ neoplastic cells was assigned to 1 of the following categories: 0%, <10%, 10%-25%, 25%-50%, 50%-75%, and >75%.
EBV status as assessed by EBER in situ hybridization.
Fibrohistiocytoid stromal cells in the background.
Epithelioid histiocytes in the background.
Occasional positivity.